GlassScriptPhysician profile
Travis W Hanson
NPI 1780666024
$1,027,498.41
in general payments reported to CMS, 2019-2025
14 companies · $89K in 2025
The $89K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $69K · 2021: $97K · 2022: $513K · 2023: $142K · 2024: $67K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $203K · Acquisitions: $57K · Consulting Fee: $20K · Travel and Lodging: $9,854 · Grant: $5,000 · Food and Beverage: $2,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $203,085.16 |
| Acquisitions | $56,652.57 |
| Consulting Fee | $20,178.23 |
| Travel and Lodging | $9,853.56 |
| Grant | $5,000.00 |
| Food and Beverage | $2,859.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $710,123.74 | 2022-2025 | Fracture and Correction Colag 2, 5ms, Colink Mini |
| In2bones USA, LLC | $309,027.63 | 2019-2022 | |
| Theramicro, INC. | $6,364.04 | 2025 | Tekbrace Solo |
| Vilex LLC | $1,169.10 | 2025 | Hintermann, Alphalok |
| Stryker Corporation | $318.09 | 2022-2025 | Infinity Adaptis, Augment Injectable |
| Pacira Therapeutics, INC. | $168.45 | 2019-2020 | |
| Depuy Synthes Sales INC. | $122.92 | 2021 | |
| Kerecis Limited | $41.98 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Treace Medical Concepts, INC. | $31.31 | 2024 | |
| Alafair Biosciences, INC. | $31.12 | 2023 | Versawrap |
| Bioventus LLC | $27.36 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Heron Therapeutics, INC. | $26.13 | 2022 | |
| Solventum Corporation | $25.54 | 2024 | V.A.C.Ulta |
| Medtronic, INC. | $21.00 | 2024 | Linq II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$55,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.